NB
CRSP icon

NBT Bank’s CRISPR Therapeutics CRSP Stock Holding History

NBT Bank’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$95 Hold
2
– – ﹤0.01% 1042
2025
Q4 		$105 Hold
2
– – ﹤0.01% 807
2025
Q3 		$130 Hold
2
– – ﹤0.01% 800
2025
Q2 		$97 Hold
2
– – ﹤0.01% 784
2025
Q1 		$68 Hold
2
– – ﹤0.01% 796
2024
Q4 		$79 Hold
2
– – ﹤0.01% 769
2024
Q3 		$94 Buy
+2
New +$101 ﹤0.01% 816

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NBT Bank's CRSP Position: Q1 2026 in Review

NBT Bank held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 2 shares worth $95. The position accounts for ﹤0.01% of the portfolio, ranked #1042.

NBT Bank first reported a position in CRSP in Q3 2024 and has held it in 7 quarters since. The position peaked at $130 in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • NBT Bank held 2 shares of CRISPR Therapeutics worth $95 as of Q1 2026.
  • NBT Bank left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of NBT Bank's portfolio in Q1 2026, its #1042 holding.
  • NBT Bank first reported a position in CRISPR Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • NBT Bank's CRISPR Therapeutics position peaked at $130 in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on NBT Bank's 13F filing for Q1 2026, filed 28 Apr 2026.